Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions

Amino Acids

Volumn 43, Issue 1, 2012, Pages 467-473

  Pini, Alessandro ^a,c   Lozzi, Luisa ^a,c   Bernini, Andrea ^a   Brunetti, Jlenia ^b   Falciani, Chiara ^a   Scali, Silvia ^a   Bindi, Stefano ^a,c   Di Maggio, Tiziana ^a   Rossolini, Gian Maria ^a,c   Niccolai, Neri ^a   Bracci, Luisa ^a,c  

^a UNIVERSITY OF SIENA   (Italy)

^b SetLance srl   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Antimicrobial peptides; Branched peptides; Cystic fibrosis; Gram negative bacteria; Peptide toxicity; Trifluoroacetic acid

Indexed keywords

ACETIC ACID; COUNTERION; LYSYLLYSYLISOLEUCYLARGINYLVALYLARGINYLLEUCYLSERYLALANYLACETATE; LYSYLLYSYLISOLEUCYLARGINYLVALYLARGINYLLEUCYLSERYLALANYLTRIFLUOROACETATE; M33 PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRONCHUS; CFTR GENE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ACINETOBACTER BAUMANNII; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BRONCHI; CELL LINE; CITROBACTER FREUNDII; EPITHELIAL CELLS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GRAM-NEGATIVE BACTERIA; HUMANS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PEPTIDE FRAGMENTS; PSEUDOMONAS; RESPIRATORY MUCOSA;

ANIMALIA; NEGIBACTERIA; TETRA;

EID: 84862762312     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1103-z     Document Type: Article

References (27)

1. G Abraham D Finkelberg LM Spooner 2008 Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis Ann Pharmacother 42 719 721 18381844 10.1345/aph.1K579 1:CAS:528:DC%2BD1cXmt1antLo%3D (Pubitemid 351619945)
2. VV Andrushchenko HJ Vogel EJ Prenner 2007 Optimization of the hydrochloric acid concentration used for trifluoroacetate removal from synthetic peptides J Pept Sci 13 37 43 17031869 10.1002/psc.793 1:CAS:528: DC%2BD2sXhvFCqs70%3D (Pubitemid 46190032)
3. TM Arnold GN Forrest KJ Messmer 2007 Polymyxin antibiotics for gram-negative infections Am J Health Syst Pharm 64 819 826 17420197 10.2146/ajhp060473 1:CAS:528:DC%2BD2sXkvFenurc%3D (Pubitemid 46625465)
4. A Beck MC Bussat C Klinquer-Hamour L Goetsch JP Aubry T Champion E Julien JF Haeuw JY Bonnefoy N Corvaia 2001 Stability and CTL activity of N-terminal glutamic acid containing peptides J Pept Res 57 528 538 11437956 10.1034/j.1399-3011.2001.00895.x 1:CAS:528:DC%2BC3cXkvVOitg%3D%3D (Pubitemid 32552194)
5. L Bracci C Falciani B Lelli L Lozzi Y Runci A Pini MG De Montis A Tagliamonte P Neri 2003 Synthetic peptides in the form of dendrimers become resistant to protease activity J Biol Chem 278 46590 46595 12972419 10.1074/jbc.M308615200 1:CAS:528:DC%2BD3sXovFKlu7k%3D (Pubitemid 37452233)
6. Bragonzi A (2010) Fighting back: peptidomimetics as a new weapon in the battle against antibiotic resistance. Sci Transl Med 2:21ps9
7. J Cornish KE Callon CQX Lin CL Xiao TB Mulvey GJS Cooper IR Reid 1999 Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes Am J Physiol 277 E779 E783 10567002 1:CAS:528:DyaK1MXns1OltLk%3D
8. C Falciani L Lozzi A Pini F Corti M Fabbrini A Bernini B Lelli N Niccolai L Bracci 2007 Molecular basis of branched peptide resistance to enzyme proteolysis Chem Biol Drug Des 69 216 221 17441908 10.1111/j.1747-0285.2007. 00487.x 1:CAS:528:DC%2BD2sXkvFSrurc%3D (Pubitemid 46608454)
9. C Falciani A Pini L Bracci 2009 Oligo-branched peptides for tumor targeting: from magic bullets to magic forks Expert Opin Biol Ther 9 171 178 19236247 10.1517/14712590802620501 1:CAS:528:DC%2BD1MXlvFeltA%3D%3D
10. C Falciani B Lelli J Brunetti S Pileri A Cappelli A Pini C Pagliuca N Ravenni L Bencini S Menichetti R Moretti M De Prizio M Scatizzi L Bracci 2010 Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: a proof-of-concept Curr Cancer Drug Targets 10 695 704 20578987 10.2174/156800910793605875 1:CAS:528:DC%2BC3cXhsVSku7nL
11. GB Fields RL Noble 1990 Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids Int J Pept Protein Res 35 161 214 2191922 10.1111/j.1399-3011.1990.tb00939.x 1:CAS:528:DyaK3cXksVWhsbg%3D (Pubitemid 20126875)
12. DC Gruenert M Willems JJ Cassiman RA Frizzell 2004 Established cell lines used in cystic fibrosis research J Cyst Fibros 3 191 196 15463957 10.1016/j.jcf.2004.05.040 1:CAS:528:DC%2BD2cXnsVyrt7Y%3D (Pubitemid 40045597)
13. MJ Little N Aubry ME Beaudoin N Goudreau SR LaPlante 2007 Quantifying trifluoroacetic acid as counterion in drug discovery by 19F NMR and capillary electrophoresis J Pharm Biomed Anal 43 1324 1330 17145157 10.1016/j.jpba.2006. 10.039 1:CAS:528:DC%2BD2sXit1Gns7o%3D (Pubitemid 46282377)
14. RB Merrifield 1963 Solid phase peptide synthesis. I. The synthesis of a tetrapeptide J Am Chem Soc 85 2149 2154 10.1021/ja00897a025 1:CAS:528: DyaF3sXksVajsLg%3D
15. A Michalopoulos ME Falagas 2008 Colistin and polymyxin B in critical care Crit Care Clin 24 377 391 18361952 10.1016/j.ccc.2007.12.003 1:CAS:528:DC%2BD1cXmtFSnsrg%3D (Pubitemid 351400615)
16. A Pini A Giuliani C Falciani Y Runci C Ricci B Lelli M Malossi P Neri GM Rossolini L Bracci 2005 Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification Antimicrob Agents Chemother 49 2665 2672 15980334 10.1128/AAC.49.7.2665-2672.2005 1:CAS:528:DC%2BD2MXlvFSmurY%3D (Pubitemid 40917576)
17. A Pini Y Runci C Falciani B Lelli J Brunetti S Pileri M Fabbrini L Lozzi C Ricci A Bernini F Tonello F Dal Molin P Neri N Niccolai L Bracci 2006 Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo Biochem J 395 157 163 16398644 10.1042/BJ20051747 1:CAS:528:DC%2BD28XitlSnsrY%3D
18. A Pini A Giuliani C Falciani M Fabbrini S Pileri B Lelli L Bracci 2007 Characterization of the branched antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity J Pept Sci 13 393 399 17486663 10.1002/psc.858 1:CAS:528:DC%2BD2sXntV2lt7s%3D (Pubitemid 46902005)
19. A Pini C Falciani L Bracci 2008 Branched peptides as therapeutics Curr Protein Pept Sci 9 468 477 18855698 10.2174/138920308785915227 1:CAS:528:DC%2BD1cXhtFKnur3N
20. A Pini C Falciani E Mantengoli S Bindi J Brunetti S Iozzi GM Rossolini L Bracci 2010 A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo FASEB J 24 1015 1022 19917670 10.1096/fj.09-145474 1:CAS:528:DC%2BC3cXktlOqsLw%3D
21. A Preiss J Kruppa J Buschmann C Mügge 1998 The determination of trifluoroacetic acid in rat milk samples by 19F-NMR spectroscopy and capillary gas chromatography J Pharm Biomed Anal 16 1381 1385 9777612 10.1016/S0731- 7085(97)00155-6 1:CAS:528:DyaK1cXislajtrc%3D (Pubitemid 28191793)
22. Reichert J et al (2010) Development trends for peptide therapeutics-Report 2010. Peptide Therapeutics Foundation, San Diego
23. J Rivier R McClintock R Galyean H Anderson 1984 Reversed-phase high-performance liquid chromatography: preparative purification of synthetic peptides J Chromatogr 288 303 328 6736144 10.1016/S0021-9673(01)93709-4 1:CAS:528:DyaL2cXksFWjsrc%3D (Pubitemid 14140560)
24. S Roux E Zékri B Rousseau M Paternostre JC Cintrat N Fay 2008 Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches J Pept Sci 14 354 359 18035848 10.1002/psc.951 1:CAS:528:DC%2BD1cXktFGhsL0%3D (Pubitemid 351385429)
25. MA Sani C Loudet G Gröbner EJ Dufourc 2007 Pro-apoptotic bax-alpha 1 synthesis and evidence for beta-sheet to alpha-helix conformational change as triggered by negatively charged lipid membranes J Pept Sci 13 100 106 17106904 10.1002/psc.803 1:CAS:528:DC%2BD2sXitVOht70%3D (Pubitemid 46290946)
26. JP Tam 1988 Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system Proc Natl Acad Sci USA 85 5409 5413 3399498 10.1073/pnas.85.15.5409 1:CAS:528:DyaL1cXls1ynuro%3D
27. RK Verbeeck I Kanfer RB Walker 2006 Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy Eur J Pharm Sci 28 1 6 16413762 10.1016/j.ejps.2005.12.001 1:CAS:528:DC%2BD28Xit1ChtL8%3D